Pharma: connecting scientific promise with evidence, access and execution

Pharmaceutical organisations often divide these responsibilities across highly expert functions. Specialisation is necessary. The difficult decisions sit between them: which evidence to generate, how to interpret uncertainty, when to change a development plan, how to prepare for access and whether the organisation can manufacture and supply what it hopes to bring to patients. A senior appointment should be framed around those interfaces, not merely the discipline named in the title.

AI can contribute across the medicines lifecycle, but its use raises questions of data provenance, reliability, validation and monitoring. The European Medicines Agency's reflection paper addresses AI from discovery through the post-authorisation setting; EMA and FDA have also published common principles for AI in medicine development. These are reference points for leadership judgement, not a licence to generalise one use case to all medicines or jurisdictions.

Define the strategic decision the leader must own

A search for a head of R&D, medical affairs, development, market access or a general-management role can look different depending on the portfolio. Is the priority to advance one asset with disciplined evidence? Coordinate a complex pipeline? Build external partnerships? Improve execution across regions? Each requires a different combination of scientific credibility, resource allocation and cross-functional leadership.

The role should specify which decisions the executive can make and where they must convene other experts. A leader who is expected to integrate functions but lacks authority over priorities or investment may be set up to mediate rather than lead.

Assess how the candidate handles uncertainty

Pharma leaders routinely act before all evidence is available, yet must not treat hope as proof. Ask candidates to describe a programme they advanced, redirected or stopped. What signal changed their view? How did they involve scientific, regulatory, medical and commercial colleagues? How did they explain a difficult decision to a team invested in a programme? An answer that acknowledges uncertainty and describes a disciplined decision is more valuable than an unbroken story of success.

The same applies to AI-enabled work. The candidate should know what was actually validated, what remained exploratory, what human experts reviewed and how the result affected a decision. “We used AI” says little about leadership unless the person can show how it improved evidence or execution while maintaining accountability.

The search should also examine how the executive works with external stakeholders. A development decision may need to be understood by regulators, clinicians, payers, partners and patients, each with different questions and evidence needs. The candidate need not have performed every specialist role. They should show that they know when to bring expertise into the decision and how to communicate uncertainty without either overstating promise or paralysing progress.

In an assessment, a useful scenario is a programme with promising early results but a manufacturing or access constraint that will affect timing. Ask what the candidate would resolve first, which work should continue and what they would tell the executive team. The answer reveals whether they can lead the full value chain rather than optimise the function they know best.

Keep the patient and the operating system in view

Scientific and commercial functions can each optimise their own milestones while the full pathway to patients remains fragile. The executive team needs a shared account of the intended benefit, evidence requirements, supply and access constraints, and the sequence of decisions. That account should inform both the candidate profile and the composition of the surrounding leadership team.

Before launching a search, the board can ask:

• Which cross-functional decision is currently most difficult to make?
• What evidence and authority will the incoming leader need to resolve it?
• Where must scientific credibility be personal, and where can a team provide specialist depth?
• How will the organisation recognise a decision to stop or redirect as good leadership when it is justified?

The strongest pharma appointment connects ambition with disciplined evidence and execution. The search should identify someone who can work across deep expertise without pretending that any one person can replace it.